ERBB2 and breast cancer: At ASCO 2012, the NSABP (B-41) protocol was presented by Robidoux et al. It is a randomized phase III trial of neoadjuvant therapy (anthracycline plus cyclophosphamide (AC) followed by weekly paclitaxel (WP) for patients with palpable and operable HER2 positive breast cancer comparing the combination of trastuzumab (T) plus lapatinib (L) to trastuzumab and to lapatinib administered with weekly paclitaxel following (AC) [16].